Angle Plc Stock Price, News & Analysis

ANGLE plc (AIM:AGL / OTCQX:ANPCY) announced a strategic refocus and management change on 8 October 2025. Dr Jan Groen moves from Non-Executive Chairman to Executive Chairman to lead a revised strategy centred on CTC intelligence and accelerated commercial traction using the Parsortix platform. The company proposes a name change to CelLBxHealth plc and an AIM ticker change to CLBX, expected mid-October.

The plan emphasises proteomics and genomics applications, tighter cost control and partnerships. Cash runway is stated through to Q1 2026, and the company expects a need to raise funds in the coming months. CEO and Finance Director will transition out over the next 12 months, with contractual entitlements honoured.

ANGLE plc (OTCQX:ANPCY) presented promising data from a proof-of-concept study in glioblastoma at the 7th Advances in Circulating Tumour Cells meeting. The study, using their Parsortix® system and CellKeep™ slides, demonstrated significant capabilities in detecting circulating tumor cells (CTCs) in glioblastoma patients.

Key findings showed CTCs were detected in 60% of patients, with CTC clusters observed in 78% of CTC-positive patients. The study revealed that 73% of subjects showed extracellular vesicles (EVs), highlighting the potential for liquid biopsy in monitoring glioblastoma. Notably, the system's label-free methodology successfully detected mesenchymal phenotype CTCs, which are typically undetectable using traditional CTC technologies.

ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, announced significant leadership changes. CEO Andrew Newland and Finance Director Ian Griffiths have agreed to step down from their positions on the Board following discussions with a major shareholder.

The current Board consists of Dr. Jan Groen as Non-executive Chairman and Dr. Joseph Eid as Non-executive Director. The company plans to expand its Board membership in the future. Both departing executives have committed to supporting an orderly transition.

ANGLE plc (OTCQX:ANPCY), a liquid biopsy company, reported its H1 2025 interim results with revenues of £0.8 million, down from £1.0 million in H1 2024. The company posted a loss of £9.3 million with cash reserves of £5.3 million extending into Q1 2026.

Key operational achievements include successful completion of contracts with Eisai and AstraZeneca, development of DNA Dual Analysis using Illumina NGS technology, and a new collaboration with Myriad Genetics. The company's Parsortix system demonstrated strong results in Eisai's Phase 2 breast cancer trial, particularly with its HER2 assay.

Despite challenging market conditions affecting revenue growth, ANGLE expects 2025 revenues to exceed £1.5 million and anticipates announcing several new high-profile collaborations in the coming months.

ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the appointment of Cavendish Capital Markets Limited as its new Nominated Adviser and Sole Broker, effective immediately.

The company, which focuses on innovative solutions for research, drug development, and clinical oncology, made this change in its advisory relationships to support its ongoing business operations. The appointment demonstrates ANGLE's commitment to maintaining strong market relationships and corporate governance standards.

ANGLE plc (OTCQX:ANPCY), a pioneering liquid biopsy company specializing in circulating tumour cell (CTC) diagnostic solutions, has scheduled the release of its interim results for H1 2025 on September 9, 2025.

The company will host a virtual analyst meeting at 11:00 am BST due to planned tube strikes. The event will include a live webcast accessible through ANGLE's Investor Centre page, with Q&A participation limited to analysts. A recording will be made available on the company's website after the meeting.

ANGLE plc (OTCQX:ANPCY) has announced a strategic collaboration with Myriad Genetics (NASDAQ:MYGN) to evaluate the feasibility of using Parsortix-derived circulating tumor cell (CTC) DNA with Myriad's existing tissue-based diagnostic tests.

Under the agreement, ANGLE's R&D team will process cancer patient blood samples using their Parsortix® system to capture intact cancer cells for molecular analysis. The study will compare CTC-DNA results with matched patient tissue samples using Myriad's current tissue-based assay. The specific terms of the agreement remain confidential between the parties.

ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company, announced a significant publication in Nature Genetics by ETH Zurich researchers utilizing the company's Parsortix® system. The study investigated genetic diversity in circulating tumor cell (CTC) clusters in breast cancer.

The research revealed that CTC clusters are up to 100 times more metastatic than individual CTCs, with metastatic spread responsible for over 90% of cancer-related deaths. The study found higher prevalence of CTC clusters in high-complexity tumors, with some mutations being exclusive to specific cells within CTC clusters that could be missed by traditional tissue biopsies.

The findings position CTC clusters as crucial targets for stopping cancer spread, highlighting Parsortix's capability to overcome spatial and temporal limitations of conventional tissue biopsy methods.

ANGLE plc (OTCQX:ANPCY), a world-leading liquid biopsy company, has announced that all resolutions presented at its 2025 Annual General Meeting were successfully passed. The company will make detailed voting results available on its corporate website.